Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 12, 2009, Pages 1968-1976

  Melis, Marleen ^a   Bijster, Magda ^a   De Visser, Monique ^a   Konijnenberg, Mark W ^b   De Swart, Jan ^a   Rolleman, Edgar J ^a   Boerman, Otto C ^c   Krenning, Eric P ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Research and Development   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Kidney; Radiolabelled octreotate; Renal reabsorption; Succinylated gelatin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; GELATIN SUCCINATE; OCTREOTATE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE]; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; MALE; NONHUMAN; RAT; RENAL PROTECTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; ISOTOPE LABELING; KIDNEY; MALE; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; POLYGELINE; RATS; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 71849094150     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1196-8     Document Type: Article

References (38)

1. EP Krenning JJ Teunissen R Valkema WW deHerder M deJong DJ Kwekkeboom 2005 Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors J Endocrinol Invest 28 11 Suppl International 146 150 1:STN:280:DC%2BD283hvFSjsA%3D%3D 16625865
2. DJ Kwekkeboom WW de Herder BL Kam CH van Eijck M van Essen PP Kooij, et al. 2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 13 2124 2130 10.1200/JCO.2007.15.2553 1:CAS:528:DC%2BD1cXms1Ort7s%3D 18445841
3. S Silbernagl 1988 The renal handling of amino acids and oligopeptides Physiol Rev 68 3 911 1007 1:CAS:528:DyaL1cXlt1KhtL4%3D 3293095
4. M Melis EP Krenning BF Bernard R Barone TJ Visser M de Jong 2005 Localisation and mechanism of renal retention of radiolabelled somatostatin analogues Eur J Nucl Med Mol Imaging 32 10 1136 1143 10.1007/s00259-005-1793-0 1:CAS:528:DC%2BD2MXhtVent7zN 15912401 (Pubitemid 41355939)
5. EI Christensen H Birn 2002 Megalin and cubilin: multifunctional endocytic receptors Nat Rev Mol Cell Biol 3 4 256 266 1:CAS:528:DC%2BD38XjslOnur4%3D 11994745
6. M de Jong R Barone E Krenning B Bernard M Melis T Visser, et al. 2005 Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide J Nucl Med 46 10 1696 1700 16204720
7. JR Duncan MJ Welch 1993 Intracellular metabolism of indium-111-DTPA- labeled receptor targeted proteins J Nucl Med 34 10 1728 1738 1:CAS:528:DyaK2cXhvVKhu78%3D 8410290
8. B Emami J Lyman A Brown L Coia M Goitei JE Munzenrider, et al. 1991 Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 1 109 122 1:STN:280:DyaK3M3js1CktA%3D%3D 2032882
9. R Barone F Borson-Chazot R Valkema S Walrand F Chauvin L Gogou, et al. 2005 Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship J Nucl Med 46 Suppl 1 99S 106S 1:CAS:528:DC%2BD2MXhsVeksLc%3D 15653658
10. L Bodei M Cremonesi M Ferrari M Pacifici CM Grana M Bartolomei, et al. 2008 Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors Eur J Nucl Med Mol Imaging 35 10 1847 1856 10.1007/s00259-008-0778-1 1:CAS:528:DC%2BD1cXhtFCjtbzP 18427807
11. BW Wessels MW Konijnenberg RG Dale HB Breitz M Cremonesi RF Meredith, et al. 2008 MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy J Nucl Med 49 11 1884 1899 10.2967/jnumed.108.053173 18927342
12. M de Jong EJ Rolleman BF Bernard TJ Visser WH Bakker WA Breeman, et al. 1996 Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo J Nucl Med 37 8 1388 1392 8708781
13. EJ Rolleman R Valkema M de Jong PP Kooij EP Krenning 2003 Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine Eur J Nucl Med Mol Imaging 30 1 9 15 10.1007/s00259-002-0982-3 1:CAS:528:DC%2BD38XpsV2iurY%3D 12483404 (Pubitemid 36692887)
14. R Valkema SA Pauwels LK Kvols DJ Kwekkeboom F Jamar M de Jong, et al. 2005 Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate J Nucl Med 46 Suppl 1 83S 91S 1:CAS:528:DC%2BD2MXhsVeksLk%3D 15653656
15. JE van Eerd E Vegt JF Wetzels FG Russel R Masereeuw FH Corstens, et al. 2006 Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats J Nucl Med 47 3 528 533 16513623
16. E Vegt JF Wetzels FG Russel R Masereeuw OC Boerman JE van Eerd, et al. 2006 Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin J Nucl Med 47 3 432 436 1:CAS:528: DC%2BD28Xlt1KmsL8%3D 16513612
17. MA ten Dam AJ Branten IS Klasen JF Wetzels 2001 The gelatin-derived plasma substitute Gelofusine causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption J Crit Care 16 3 115 120 10.1053/jcrc.2001.28787 11689768 (Pubitemid 33043107)
18. BA Veldman HL Schepkens G Vervoort I Klasen JF Wetzels 2003 Low concentrations of intravenous polygelines promote low-molecular weight proteinuria Eur J Clin Invest 33 11 962 968 10.1046/j.1365-2362.2003.01258.x 1:CAS:528:DC%2BD3sXpvFSnt78%3D 14636299 (Pubitemid 37421594)
19. M Gotthardt J van Eerd-Vismale WJ Oyen M de Jong H Zhang E Rolleman, et al. 2007 Indication for different mechanisms of kidney uptake of radiolabeled peptides J Nucl Med 48 4 596 601 10.2967/jnumed.106.036020 1:CAS:528: DC%2BD2sXhtVert7nF 17401097 (Pubitemid 47571416)
20. EJ Rolleman BF Bernard WA Breeman F Forrer E de Blois J Hoppin, et al. 2008 Molecular imaging of reduced renal uptake of radiolabelled [DOTA0, Tyr3]octreotate by the combination of lysine and Gelofusine in rats Nuklearmedizin 47 3 110 115 1:CAS:528:DC%2BD1cXotFalu7w%3D 18493690
21. M de Jong WA Breeman BF Bernard WH Bakker M Schaar A van Gameren, et al. 2001 [177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy Int J Cancer 92 5 628 633 10.1002/1097-0215(20010601)92: 5<628::AID-IJC1244>3.0.CO;2-L 11340564 (Pubitemid 32385702)
22. WA Breeman M De Jong TJ Visser JL Erion EP Krenning 2003 Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities Eur J Nucl Med Mol Imaging 30 6 917 920 1:CAS:528:DC%2BD3sXjvF2lsb4%3D 12677301
23. BF Bernard E Krenning WA Breeman TJ Visser WH Bakker A Srinivasan, et al. 2000 Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy Nucl Med Commun 21 11 1079 1085 10.1097/00006231-200011000-00015 1:CAS:528:DC%2BD3MXktlSktw%3D%3D 11192715
24. F Forrer R Valkema B Bernard NU Schramm JW Hoppin E Rolleman, et al. 2006 In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals Eur J Nucl Med Mol Imaging 33 10 1214 1217 10.1007/s00259-006-0178-3 1:STN:280:DC%2BD28rnvVGhtA%3D%3D 16832630 (Pubitemid 44484478)
25. MW Konijnenberg M Bijster EP Krenning M De Jong 2004 A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu J Nucl Med 45 7 1260 1269 1:CAS:528:DC%2BD2cXnsFygsbk%3D 15235075
26. MG Stabin MW Konijnenberg 2000 Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes J Nucl Med 41 1 149 160 1:STN:280:DC%2BD3c7ht1Wntg%3D%3D 10647618
27. O Schober K Rahbar B Riemann 2009 Multimodality molecular imaging-from target description to clinical studies Eur J Nucl Med Mol Imaging 36 2 302 314 10.1007/s00259-008-1042-4 1:STN:280:DC%2BD1M%2Fpslynsg%3D%3D 19130054
28. A Otte R Herrmann A Heppeler M Behe E Jermann P Powell, et al. 1999 Yttrium-90 DOTATOC: first clinical results Eur J Nucl Med 26 11 1439 1447 10.1007/s002590050476 1:CAS:528:DyaK1MXms1Kntbo%3D 10552085 (Pubitemid 29515605)
29. M Cybulla SM Weiner A Otte 2001 End-stage renal disease after treatment with 90Y-DOTATOC Eur J Nucl Med 28 10 1552 1554 10.1007/s002590100599 1:CAS:528:DC%2BD3MXmvFSlu7g%3D 11685499
30. L Bodei M Cremonesi C Grana P Rocca M Bartolomei M Chinol, et al. 2004 Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours Eur J Nucl Med Mol Imaging 31 7 1038 1046 10.1007/s00259-004-1571-4 1:CAS:528:DC%2BD2cXltF2hsr8%3D 15150675
31. DJ Kwekkeboom JJ Teunissen WH Bakker PP Kooij WW de Herder RA Feelders, et al. 2005 Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors J Clin Oncol 23 12 2754 2762 10.1200/JCO.2005.08.066 1:CAS:528:DC%2BD2MXktleqtrk%3D 15837990 (Pubitemid 46179465)
32. H Akizawa Y Arano M Mifune A Iwado Y Saito T Mukai, et al. 2001 Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides Nucl Med Biol 28 7 761 768 10.1016/S0969-8051(01)00241-4 1:CAS:528:DC%2BD3MXntV2htL0%3D 11578896 (Pubitemid 32900633)
33. PJ Janssen M de Visser SM Verwijnen BF Bernard A Srinivasan JL Erion, et al. 2007 Five stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors Cancer Biother Radiopharm 22 3 374 381 10.1089/cbr.2007.369.A 1:CAS:528:DC%2BD2sXotFygsbY%3D 17651043
34. S Knör S Sato T Huber A Morgenstern F Bruchertseifer M Schmitt, et al. 2008 Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer Eur J Nucl Med Mol Imaging 35 1 53 64 10.1007/s00259-007-0582-3 17891393 (Pubitemid 350234153)
35. J Nagai M Takano 2004 Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity Drug Metab Pharmacokinet 19 3 159 170 10.2133/dmpk.19.159 1:CAS:528:DC%2BD2cXmvFKqs78%3D 15499183
36. V Prasad S Fetscher RP Baum 2007 Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view J Pharm Pharm Sci 10 2 321s 337s 1:CAS:528:DC%2BD2sXptlKrtrg%3D 17718935
37. ME Barron MM Wilkes RJ Navickis 2004 A systematic review of the comparative safety of colloids Arch Surg 139 5 552 563 10.1001/archsurg.139.5. 552 1:CAS:528:DC%2BD2cXks1Kitr4%3D 15136357 (Pubitemid 38585756)
38. EJ Rolleman M de Jong R Valkema D Kwekkeboom B Kam EP Krenning 2006 Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine? J Nucl Med 47 10 1730 1731 17015911 author reply 1731